Zealand Pharma stock

ZEAL · Nasdaq Copenhagen · DKK

kr 246.60Change from previous close: +1.90%Absolute change: +kr 4.60

Close · November 16, 2026

Price history

−52.97% over the period

1 year: from kr 524.40 (November 17, 2025) to kr 246.60 (November 16, 2026), −52.97%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026kr 246.60
October 30, 2026kr 234.10
September 30, 2026kr 271.10
August 31, 2026kr 300.00
July 31, 2026kr 304.00
June 30, 2026kr 289.60
May 29, 2026kr 324.90
April 30, 2026kr 299.40
March 31, 2026kr 295.00
February 27, 2026kr 363.80
January 30, 2026kr 420.10
December 30, 2025kr 466.40
November 28, 2025kr 516.40
November 17, 2025kr 524.40

At a glance

  • The company

    Biotechnology company developing peptide-based medicines for gastrointestinal and metabolic diseases, including Zegalogue for severe hypoglycemia treatment

  • Latest results

    Quarter to September 30, 2026 · EPS -kr 10.02 (estimate -kr 9.63)

TickerLandia's take on Zealand Pharma

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowkr 220.60
52-wk highkr 556.00

−55.65% from the 52-week high

Analysts · 16 analysts

Average targetkr 386.08+56.56% vs. price

Buy 6 · Hold 9 · Sell 1 · Buy

TickerLandia Fingerprint: Zealand Pharma

Compared with similar companies: very weak momentum, very high risk, and very high profitability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Zealand Pharma is cheaper than similar companies

Zealand Pharma's P/E (trailing 12 months): 5.49, −68% against the median of a group of 9 similar companies (17.1).

Compared with 9 similar companies

Zealand Pharma's metrics compared with similar companies
MetricZealand PharmaPosition in the groupBand
P/E (trailing 12 months)5.49Low
Forward P/E33.4Middle
Operating margin59.0%High
ROE19.1%Middle
Debt/equity0.03Middle

Grey band: the middle half of the group; tick: the median; dot: Zealand Pharma. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

kr 4.49B

Latest quarter · Q2 2026

Net income

kr 3.92B

Latest quarter · Q2 2026

Quarterly net margin

87.2%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
kr 16.05B
P/E
5.5
EPS
kr 44.12
Volume
388.91K
Daily trading
€11.4M
Dividend yield
0.00%

How Zealand Pharma is changing

All results
  • Revenue grew 116.9% a year on average over the last 5 years

  • Operating margin rose from −785.3% to 75.1%

  • Profits turn into cash: free cash flow equal to 110% of net income

Returns

Zealand Pharma returns

kr 1,000 invested in Zealand Pharma 5 years ago, on November 16, 2021, would be worth kr 1,561 today: +56.08% in total, +9.31% per year. This is the price return only: dividends are excluded.

PeriodZealand Pharmakr 1,000 becomes
1 month+8.97%kr 1,090
6 months−20.61%kr 794
Year to date−47.13%kr 529
1 year−52.97%kr 470
3 years−19.25%kr 807
5 years+56.08%kr 1,561
10 years+122.16%kr 2,222

Price only, without dividends. Calculate your investment

The chart in detail

Zealand Pharma: technical analysis

Zealand Pharma is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 74.2% below its all-time closing high (kr 954.00, July 10, 2024).

Trend
Downward
RSI (14 sessions)
54
Between 30 and 70
vs 200-session average
−18.00%

Support and resistance

Price areas where Zealand Pharma has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistancekr 306.28+24.20%6 touches, last on August 18, 2026
  2. Resistancekr 294.93+19.60%4 touches, last on September 18, 2026
  3. Resistancekr 272.05+10.32%4 touches, last on September 16, 2026
  4. Last pricekr 246.60
  5. Supportkr 235.50−4.50%2 touches, last on June 8, 2026
  6. Supportkr 220.85−10.44%2 touches, last on October 27, 2026

Volatility and risk

Volatility (60 sessions, annualised)
37.0%
Largest fall in the last year
−59.36%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Zealand Pharma: seasonality

Average monthly price change over 16 years

+5.1%Jan−1.1%Feb+2.1%Mar+0.1%Apr+1.9%May−1.0%Jun+7.2%Jul−2.1%Aug+4.2%Sep+0.3%Oct−1.7%Nov+0.5%Dec

Over the last 16 years, the strongest month for Zealand Pharma has been July: +7.23% on average, positive in 11 years out of 16. The weakest has been August: −2.07% on average, positive in 6 years out of 16. November, the current month, has been positive in 7 years out of 15 (−1.68% on average).

Show chart data
MonthAverageMedianPositive years
January+5.14%+4.78%11 of 16
February−1.15%−2.40%5 of 16
March+2.11%+2.45%9 of 16
April+0.12%+0.41%9 of 16
May+1.85%+0.59%9 of 16
June−1.04%−3.56%7 of 16
July+7.23%+4.59%11 of 16
August−2.07%−2.06%6 of 16
September+4.22%+1.81%9 of 16
October+0.32%+0.38%8 of 16
November−1.68%−0.66%7 of 15
December+0.55%−0.99%6 of 16

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Zealand Pharma and its competitors

Patients with gastrointestinal and metabolic conditions, as well as those with other specialty diseases where treatment options remain limited, are the people the company's medicines are designed for. Zealand Pharma works across Denmark and the US, where it researches, develops and commercializes medicines built on peptides. Its product Zegalogue, a single-dose device for severe low blood sugar, sits alongside dasiglucagon-based systems for artificial pancreas use that combine insulin and dasiglucagon.

Headquarters
Søborg, Denmark
Employees
605
Founded
1997
Chief executive
Adam Steensberg
Zealand Pharma and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Zealand PharmaZEAL$2.37B59.0%5.49−20.61%
Bavarian NordicBAVA$2.62B18.1%12.2+26.18%
Lakefront BiotherapeuticsLKFT$2.2B57.5%3.21+33.42%
BioArcticBIOA.B$2.74B19.6%262.7−3.82%
CamurusCAMX$4.41B37.4%58.9+46.61%
Pharma MarPHM$1.28B21.3%17.1−29.91%

Same industry or related industries, similar size. Compare Zealand Pharma with its competitors · Full profile